Abstract

It has long been difficult to determine hydralazine in biological fluids for biopharmaceutical and pharmacokinetic purposes. The drug can react with a number of endogenous compounds, e.g. pyruvic acid or ±-ketoglutaric acid, to form acid-labile hydrazones. Being a base, hydralazine is extractable from biological fluids only at basic pH values where it is unstable, being degraded mainly to phthalazine. A derivatization procedure which can be carried out directly in biological fluids is therefore essential.

Keywords

Biological Fluid Pyruvic Acid Derivatization Procedure Bioavailability Study Stable Derivative 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Noda, H., Minemoto, M., Noda, A. & Ushio, T. (1986) Chem. Pharm. Bull. 34, 3499–3501.CrossRefGoogle Scholar
  2. 2.
    Schmid, K., Küng, W., Riess, W., Dollery, C.T. & Harland, S.J. (1987) Arzneim.-Forsch. 31, 1143–1147.Google Scholar
  3. 3.
    Dubois, J.P., Schmid, K., Riess, W., Hanson, A., Henningsen, N.C.N. & Andersson, O.K. (1987) Arzneim.-Forsch. 37, 189–193.Google Scholar
  4. 4.
    Reece, P.A., Cozamanis, I. & Zacest, R. (1980) J. Chromatog. 181, 427–440.Google Scholar
  5. 5.
    Ludden, T.M., Ludden, L.K., McNay, J.L., Skrdlant, H.B., Swaggerty, P.J. & Shepherd, A.M.M. (1980) Anal. Chim. Acta 120, 297–304.CrossRefGoogle Scholar
  6. 6.
    Perry, H.M. (1953) J. Lab. Clin. Med. 41, 566–573.Google Scholar
  7. 7.
    Schulert, A.R. (1961) Arch. Int. Pharmacodyn. 132, 1–15.Google Scholar
  8. 8.
    Zacest, R. & Kock-Weser, J. (1972) Clin. Pharm. Ther. 13, 420–425.Google Scholar
  9. 9.
    Zak, S.V., Bartlett, M.F., Wagner, W.E., Gilleran, T.G. & Lukas, G. (1974) J. Pharm. Sci. 63, 225–229.CrossRefGoogle Scholar
  10. 10.
    Jack, D.B., Brechbühler, S., Degen, P.H., Zbinden, P. & Riess, W. (1975) J. Chromatog. 115, 87–92.CrossRefGoogle Scholar
  11. 11.
    Haegele, K.D., Skrdlant, H.B., Robie, N.W., Lalka, D. & McNay, J.L. (1976) J. Chromatog. 126, 517–534.CrossRefGoogle Scholar
  12. 12.
    Zak, S.B., Lukas, G. & Gilleran, G.T. (1977) Drug Metab. Dispos. 5, 116–121.Google Scholar
  13. 13.
    Smith, K.M., Johnson, R.N. & Kho, B.T. (1977) J. Chromatog. 137, 431–437.CrossRefGoogle Scholar
  14. 14.
    Reece, P.A., Stanley, P.E. & Zacest, R. (1978) J. Pharm. Sci. 67, 1150–1153.CrossRefGoogle Scholar
  15. 15.
    Degen, P.H. (1979) J. Chromatog. 176, 375–380.CrossRefGoogle Scholar
  16. 16.
    Proveaux, W.J., O’Donnell, J.P. & Ma, J.K.K. (1979) J. Chromatog. 176, 480–484.CrossRefGoogle Scholar
  17. 17.
    Angelo, H.R., Christensen, J.M., Kristensen, M. & McNair, A. (1980) J. Chromatog. 183, 159–166.Google Scholar
  18. 18.
    Haegele, K.D., Skrdlant, H.B., Talseth, T., McNay, J.L., Shepherd, A.M.M. & Clementi, W.A. (1980) J. Chromatog. 187, 171–179.CrossRefGoogle Scholar
  19. 19.
    Facchini, V., Streeter, A.J. & Timbrell, J.A. (1980) J. Chromatog 187, 218–223.CrossRefGoogle Scholar
  20. 20.
    Ludden, T.M., Ludden, L.K., Wade, W.E. & Allerheiligen, S.R.B. (1983) J. Pharm. Sci. 72, 693–695.CrossRefGoogle Scholar
  21. 21.
    Jendryczko, A., Drozdz, M. & Magner, K. (1984) Rev. Roum. Biochim. 21, 299–301.Google Scholar
  22. 22.
    Ravichandran, K. & Baldwin, R.P. (1985) J. Chromatog. 343, 99–108.Google Scholar
  23. 23.
    Rouan, M.C. & Campestrini, J. (1985) J. Pharrn. Sci. 74, 1270–1273.CrossRefGoogle Scholar
  24. 24.
    Wang, J., Tapia, T. & Bonakdar, M. (1986) Analyst 111, 1245–1248.CrossRefGoogle Scholar
  25. 25.
    Lacagnin, L.B., Colby, H.D. & O’Donnell, J.P. (1986) J. Chromatog. 377, 319–327.Google Scholar
  26. 26.
    Wong, J.K., Joyce III, T.H. & Morrow, D.H. (1987) J. Chromatog. 385, 261–266.CrossRefGoogle Scholar
  27. 27.
    McIsaac, W.M. & Kanda, M. (1964) J. Pharmacol. Exp. Ther. 143, 7–13.Google Scholar
  28. 28.
    Reidenberg, M.M., Drayer, D., DeMarco, A.L. & Bello, C.T. (1973) Clin. Pharmacol. Ther. 14, 970–977.Google Scholar
  29. 29.
    Lesser, J.M., Israili, Z.H., Davis, D.C. & Dayton, P.G. (1974) Drug Metab. Dispos. 2, 351–360.Google Scholar
  30. 30.
    Talseth, T. (1976) Eur. J. Clin, Pharmacol. 10, 183–187/311-317/395-401.CrossRefGoogle Scholar
  31. 31.
    Talseth, T., Fauchald, P. & Pape, J.F. (1977) Current Ther. Res. 21, 157–168.Google Scholar
  32. 32.
    Melander, A., Danielson, K., Hanson, A., Rudell, B., Schersten, B., Thulin, T. & Wahlin, E. (1977) Clin. Pharm. Ther. 21, 104–107.Google Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • P. H. Degen
    • 1
  1. 1.Research and Development, Pharmaceuticals DivisionCiba-Geigy Ltd.BasleSwitzerland

Personalised recommendations